Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod to Treat Ulcerative Colitis Pharmaceutical Investing
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® in Canada Pharmaceutical Investing
DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan Pharmaceutical Investing
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® in adults with paroxysmal nocturnal hemoglobinuria Life Science Investing News
Novartis receives FDA approval for Fabhalta® , offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH Life Science Investing News
